Cargando…

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?

Worldwide, there is a shifting paradigm from immediate surgery with adjuvant treatment to a neoadjuvant approach for patients with resectable or borderline resectable pancreatic cancer (RPC or BRPC). Comparison of neoadjuvant and adjuvant studies is extremely difficult because of a great difference...

Descripción completa

Detalles Bibliográficos
Autores principales:	Versteijne, Eva, de Hingh, Ignace H. J. T., Homs, Marjolein Y. V., Intven, Martijn P. W., Klaase, Joost M., van Santvoort, Hjalmar C., de Vos-Geelen, Judith, Wilmink, Johanna W., van Tienhoven, Geertjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882845/ https://www.ncbi.nlm.nih.gov/pubmed/35237500 http://dx.doi.org/10.3389/fonc.2021.744161

Ejemplares similares

Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials
por: Doppenberg, Deesje, et al.
Publicado: (2023)

Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Janssen, Quisette P., et al.
Publicado: (2021)

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
por: Janssen, Q. P., et al.
Publicado: (2021)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
por: Versteijne, Eva, et al.
Publicado: (2016)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
por: Giovinazzo, Francesco, et al.
Publicado: (2020)

Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model
por: Latenstein, Anouk E. J., et al.
Publicado: (2020)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
por: Oshima, Minoru, et al.
Publicado: (2020)

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
por: Katz, Matthew H G, et al.
Publicado: (2023)

Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study
por: Pijnappel, Esther N., et al.
Publicado: (2022)

Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease
por: Ishikura, Satoshi, et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

Impact of network treatment in patients with resected pancreatic cancer on use and timing of chemotherapy and survival
por: Hopstaken, Jana S, et al.
Publicado: (2023)

Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials
por: Hajibandeh, Shahab, et al.
Publicado: (2023)

Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer
por: Rombouts, Steffi J., et al.
Publicado: (2016)

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
por: van Dam, J. L., et al.
Publicado: (2023)

Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
por: Mikulic, Danko, et al.
Publicado: (2021)

Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis
por: Naito, Yoshiki, et al.
Publicado: (2019)

Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons
por: Nichols, Romaine Charles, et al.
Publicado: (2019)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis
por: Groen, Jesse V, et al.
Publicado: (2021)

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial
por: Dickhoff, Chris, et al.
Publicado: (2020)

Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study
por: Latenstein, Anouk E. J., et al.
Publicado: (2020)

Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival in Pancreatoduodenectomy for Pancreatic Cancer
por: Augustinus, Simone, et al.
Publicado: (2023)

Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
por: Kim, Hyeong Seok, et al.
Publicado: (2017)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

Preoperative neoadjuvant chemoradiotherapy provides borderline resectable thoracic esophageal cancer with equivalent treatment results as clinically T3 thoracic esophageal cancer
por: Wakita, Akiyuki, et al.
Publicado: (2023)

Chyle Leak After Pancreatoduodenectomy: Clinical Impact and Risk Factors in a Nationwide Analysis
por: Augustinus, Simone, et al.
Publicado: (2023)

Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design
por: Doppenberg, D., et al.
Publicado: (2022)

Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design
por: Doppenberg, D., et al.
Publicado: (2023)

ASO Author Reflections: Nationwide Reflection of Clinical Outcomes in Elderly Patients after Resection of Pancreatic Cancer
por: Henry, Anne Claire, et al.
Publicado: (2022)

Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer
por: Imamura, Masafumi, et al.
Publicado: (2021)

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Cloyd, Jordan M., et al.
Publicado: (2020)

ASO Author Reflections: The Need for Improvement of the 8th American Joint Committee on Cancer TNM Staging System for Resected Pancreatic Ductal Adenocarcinoma
por: Schouten, Thijs J., et al.
Publicado: (2022)

Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study
por: Heinrich, Stefan, et al.
Publicado: (2019)

Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer
por: Schouten, Thijs J., et al.
Publicado: (2022)

Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer
por: Fiore, Michele, et al.
Publicado: (2017)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5lqh2ej2buq0s85tir93f6ke3l